stocktrademan
10 years ago
$NRIFF recent news/filings
bullish
## source: finance.yahoo.com
Tue, 10 Mar 2015 01:33:14 GMT ~ Nuvo Research® Provides Business Update
[at noodls] - Mississauga, Ontario, Canada - March 5, 2015 - Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today provided a business update. ...
read full: http://www.noodls.com/view/DDD8883BA64369F0EC4BAF06607DC603C9C164E9
*********************************************************
Thu, 05 Mar 2015 12:30:00 GMT ~ Nuvo Research® Provides Business Update
[CNW Group] - Nuvo Research® Provides Business Update
read full: http://finance.yahoo.com/news/nuvo-research-provides-business-123000234.html
*********************************************************
Fri, 20 Feb 2015 17:45:00 GMT ~ NRI.TO: Cash Balance and Pending Phase 3 Trial with Pennsaid 2% Keep Nuvo Research Looking Attractive
read full: http://finance.yahoo.com/news/nri-cash-balance-pending-phase-174500855.html
*********************************************************
Thu, 19 Feb 2015 22:00:00 GMT ~ Nuvo Research® Announces 2014 Fourth Quarter & Year-End Results
[CNW Group] - Nuvo Research® Announces 2014 Fourth Quarter & Year-End Results
read full: http://finance.yahoo.com/news/nuvo-research-announces-2014-fourth-220000846.html
*********************************************************
Fri, 30 Jan 2015 16:30:00 GMT ~ NRI.TO: WF10 Fails Phase 2 Allergic Rhinitis Study
read full: http://finance.yahoo.com/news/nri-wf10-fails-phase-2-163000976.html
*********************************************************
$NRIFF charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$NRIFF company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/NRIFF/company-info
Ticker: $NRIFF
OTC Market Place: OTC Pink Current
CIK code: 0001371679
Company name: Nuvo Research Inc.
Company website: http://www.nuvoresearch.com
Incorporated In: Canada
Business Description: Nuvo Research Inc. is a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10.
$NRIFF share structure
## source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: l PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "
CommonCents4Dollars
10 years ago
My thoughts, BUY, WF10 top line results are to be released mid-February as per Nuvo NR.
Nuvo Research currently sitting on $5 CASH per share, no debt, revenue generating drugs plus potential blockbuster drug WF10.
Again, my thoughts, BUY, this stock is on sale based on the big picture.
stocktrademan
10 years ago
$NRIFF DD Notes ~ http://www.ddnotesmaker.com/NRIFF
bullish
$NRIFF recent news/filings
## source: finance.yahoo.com
Thu, 13 Nov 2014 12:30:00 GMT ~ Nuvo Research® reacquires Pennsaid® 2% rights to South America, Central America, South Africa and Israel
[CNW Group] - Nuvo Research® reacquires Pennsaid® 2% rights to South America, Central America, South Africa and Israel
read full: http://finance.yahoo.com/news/nuvo-research-reacquires-pennsaid-2-123000758.html
*********************************************************
Mon, 10 Nov 2014 22:00:00 GMT ~ Nuvo Research® Announces 2014 Third Quarter Results
[CNW Group] - Nuvo Research® Announces 2014 Third Quarter Results
read full: http://finance.yahoo.com/news/nuvo-research-announces-2014-third-220000285.html
*********************************************************
Mon, 03 Nov 2014 05:01:00 GMT ~ Nuvo Research® plans Phase 3 study of Pennsaid® 2% to support international regulatory approvals
[CNW Group] - Nuvo Research® plans Phase 3 study of Pennsaid® 2% to support international regulatory approvals
read full: http://finance.yahoo.com/news/nuvo-research-plans-phase-3-050100761.html
*********************************************************
Mon, 20 Oct 2014 17:50:00 GMT ~ NRIFF: Nuvo Research Sells U.S. Pennsaid Rights To Horizon
read full: http://finance.yahoo.com/news/nriff-nuvo-research-sells-u-175000187.html
*********************************************************
Fri, 17 Oct 2014 12:13:58 GMT ~ Nuvo Sells Pennsaid 2% U.S. Rights for US$45M to Horizon Pharma
[at noodls] - NUVO RESEARCH® SELLS PENNSAID® 2% U.S. RIGHTS FOR US$45 MILLION TO HORIZON PHARMA -- Nuvo to Host Conference Call/Webcast at 8:30 a.m. ET -- Mississauga, Ontario, Canada - October 17, 2014 - Nuvo Research ...
read full: http://www.noodls.com/view/8A5BFE87B6AEFC4B5E1F0252FFF470E4AF6957FE
*********************************************************
$NRIFF charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$NRIFF company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/NRIFF/company-info
Ticker: $NRIFF
OTC Market Place: OTC Pink Current
CIK code: 0001371679
Company name: Nuvo Research Inc.
Company website: http://www.nuvoresearch.com
Incorporated In: Canada
Business Description: Nuvo Research Inc. is a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10.
$NRIFF share structure
## source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$NRIFF extra dd links
Company name: Nuvo Research Inc.
Company website: http://www.nuvoresearch.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=NRIFF+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=NRIFF+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=NRIFF+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/NRIFF/news - http://finance.yahoo.com/q/h?s=NRIFF+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/NRIFF/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/NRIFF/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=NRIFF+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/NRIFF
DTCC (dtcc.com): http://search2.dtcc.com/?q=Nuvo+Research+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Nuvo+Research+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Nuvo+Research+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.nuvoresearch.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.nuvoresearch.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.nuvoresearch.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/NRIFF
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001371679&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/NRIFF/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/NRIFF/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=NRIFF&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=NRIFF
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/NRIFF/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=NRIFF+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=NRIFF+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=NRIFF
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=NRIFF
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=NRIFF+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/NRIFF/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=NRIFF+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/NRIFF.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=NRIFF
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/NRIFF/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/NRIFF
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/NRIFF
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/NRIFF:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=NRIFF
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=NRIFF
$NRIFF DD Notes ~ http://www.ddnotesmaker.com/NRIFF
mybikeisorange
10 years ago
Then there is this from today. Market study results for WF10. Highlighted parts are mine:
http://www.prnewswire.com/news-releases/nuvo-research-completes-wf10-us-market-study-for-treatment-of-refractory-allergies-280027142.html
Nuvo Research® Completes WF10™ U.S. Market Study for Treatment of Refractory Allergies
MISSISSAUGA, ON, Oct. 22, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced the results of a market study commissioned to investigate the U.S. opportunity for the Company's experimental immunotherapy product, WF10, as a treatment for patients with refractory allergic rhinitis. The study, performed by Psscion Lifesciences Consulting (Psscion), forecasts that WF10 could capture 10-15% of the U.S. refractory allergic rhinitis market with peak U.S. annual sales of US$0.7 billion to US$1.1 billion.
"This market study confirms the significant U.S. market opportunity for WF10 to treat refractory allergic rhinitis," said Dr. Henrich Guntermann, President of Nuvo's Europe & Immunology Group. "Our clinical and case study data suggests that WF10 is a revolutionary therapy that provides symptomatic relief from multiple airborne allergens for up to 2 years after only 5 days of treatment. We are eagerly awaiting results in Q1 2015 of our ongoing 183 patient Phase 2 allergic rhinitis clinical study that is designed to confirm the positive results achieved in our earlier 60 patient Phase 2 proof-of-concept study."
About The Psscion Study
The market study was conducted by Psscion, a U.S. based firm that provides strategic advice and market research to the pharmaceutical industry. Psscion was retained to assist Nuvo in determining the optimum strategy to maximize the value of WF10 for the treatment of refractory allergic rhinitis. In the course of the study, Psscion interviewed patients with refractory allergic rhinitis, practicing physicians specializing as allergists and immunologists and representatives from insurance companies and other payers. The additional findings in the study were:
Physicians were impressed by WF10's efficacy, long-lasting therapeutic effect, ability to treat multiple allergens with one dosing regimen and favourable safety profile as observed in the Company's completed 60 patient Phase 2 proof-of-concept study and case studies;
Patients and physicians believe that WF10 would address an unmet need in the treatment of refractory allergic rhinitis;
WF10 could be an attractive alternative to subcutaneous immunotherapy (SCIT) also known as "allergy shots" which are allergen specific and can continue for months or years causing many patients to either refuse or discontinue SCIT treatment; and
Payers rated WF10 positively and felt that WF10 was unlikely to face significant barriers to coverage.
About the Company's Ongoing WF10 Phase 2 Clinical Trial
This 16 week clinical trial is a randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of a regimen of five infusions of either WF10 or its main constituents (sodium chlorite and sodium chlorate) relative to saline control in allergic rhinitis patients experiencing persistence or recurrence of symptomatic episodes in spite of conventional treatment over the previous year. The trial will measure total nasal symptom score (TNSS) and other secondary endpoints. The trial is being conducted at 15 sites in Germany. It is fully enrolled with 183 patients participating. Top-line results are expected in Q1 2015. The trial is designed to confirm the results of the Company's 2010 60 patient, randomized, double-blind, placebo-controlled, single-center Phase 2 clinical study of WF10 for the treatment of allergic rhinitis which achieved statistical significance (P<0.001) for its primary endpoint (change in TNSS at week 3).
About Refractory Allergic Rhinitis
Allergic rhinitis, a highly prevalent condition characterized by nasal symptoms (runny, blocked, or itchy nose; chronic sneezing) is triggered by an inappropriate immune response to one or more allergens such as pollens, house dust mites and pet dander. Refractory allergic rhinitis patients often suffer from severe symptoms and do not respond adequately to common forms of treatment such as antihistamines and nasal corticosteroids. Most refractory allergic rhinitis patients suffer from multiple allergies.
About WF10
WF10 is a solution containing stabilized chlorite ions that focuses on supporting the immune system by targeting the macrophage, a type of white blood cell that coordinates much of the immune system, to regulate normal immune function. WF10 is an infusion therapy currently approved only in Thailand under the name IMMUNOKINE for the treatment of post-radiation-therapy syndrome.
mybikeisorange
10 years ago
I'll try to resurrect this board as lots of good news has started to flood in. After the sale of Pennsaid 2% to Horizon, NRIFF now has $67M in cash. Currently more cash per share than price per share:
http://searchingwallstreet.com/nriff-nuvo-research-sells-u-s-pennsaid-rights-to-horizon/
NRIFF: Nuvo Research Sells U.S. Pennsaid Rights To Horizon
October 20, 2014 admin Small Cap
By David Bautz, PhD & Jason Napodano, CFA
OTC:NRIFF
TSX:NRI.TO
On October 17, 2014 Nuvo Research (OTC:NRIFF) (TSX:NRI.TO) announced it completed the sale of the company’s Pennsaid 2% U.S. sales and marketing rights to Horizon Pharma (Nasdaq: HZNP) for a cash payment of $ 45 million (CAD$ 50 million). Horizon will begin commercialization of Pennsaid 2% on January 1, 2015. Nuvo continues to retain all rights to Pennsaid and Pennsaid 2% outside the U.S. and is intending to seek a marketing partner or partners for international territories.
As part of the agreement with Horizon, Nuvo will be the exclusive supplier of Pennsaid 2% to Horizon for the U.S. market. Based on the level of sales that Horizon is able to generate for Pennsaid 2%, there could be some additional upside to Nuvo through the manufacturing mark-up. In the past we have forecasted that Pennsaid 2% peak U.S. sales are roughly $ 50 million. We believe Nuvo’s manufacturing and supply agreement with Horizon equates to an additional low-single digit royalty on these sales at full scale.
This deal follows the announcement last month that Nuvo had settled the litigation with Mallinckrodt (NYSE: MNK) that included the return of all U.S. marketing and sales rights to Pennsaid and Pennsaid 2% along with a cash payment of $ 10 million USD. We believed that Nuvo would move quickly on licensing or selling the U.S. rights to Pennsaid 2% following the litigation settlement and had predicted that a deal was likely to bring in approximately $ 20-$ 30 million USD with royalties in the mid- to high-teens. Thus, our prediction was not too far from what Nuvo ended up with by selling the full rights unencumbered by royalties.
Nuvo exited the second quarter ending June 30, 2014 with $ 10.7 million CAD in the bank. We estimate burn for the third quarter 2014 was roughly $ 2.5 million CAD. Adding in the $ 10 million USD payment from Mallinckrodt and this new $ 45 million USD payment from Horizon, we now forecast that Nuvo is sitting on approximately $ 67 million CAD in cash.
We remind investors that Nuvo will be reporting top-line results from the Phase 2 clinical trial of WF10 for the treatment of allergic rhinitis in the first quarter of 2015. The large amount of cash that the company now has will aid in funding the company’s continued development of WF10, including further studies into WF10’s mechanism of action and dosing studies to determine the minimum effective dose. We provided investors a brief update on WF10 in August 2014.
Since our last Zacks Report on Nuvo on Sep. 16, 2014, the stock has risen close to 50%. Even so, we still believe the stock is undervalued as the company currently has close to $ 5.00 per share in cash. The next catalyst will be release of the Phase 2 data for WF10, with positive results likely to send the stock significantly higher. We are maintaining our ‘Buy’ rating and a $ 7.50 price target.
READ THE LATEST FULL RESEARCH REPORT HERE
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR and to view our disclaimer.
stocktrademan
10 years ago
$NRIFF DD Notes ~ http://www.ddnotesmaker.com/NRIFF
bullish
$NRIFF recent news/filings
## source: finance.yahoo.com
Mon, 20 Oct 2014 17:50:00 GMT ~ NRIFF: Nuvo Research Sells U.S. Pennsaid Rights To Horizon
read full: http://finance.yahoo.com/news/nriff-nuvo-research-sells-u-175000187.html
*********************************************************
Fri, 17 Oct 2014 12:13:58 GMT ~ Nuvo Sells Pennsaid 2% U.S. Rights for US$45M to Horizon Pharma
[at noodls] - NUVO RESEARCH® SELLS PENNSAID® 2% U.S. RIGHTS FOR US$45 MILLION TO HORIZON PHARMA -- Nuvo to Host Conference Call/Webcast at 8:30 a.m. ET -- Mississauga, Ontario, Canada - October 17, 2014 - Nuvo Research ...
read full: http://www.noodls.com/view/8A5BFE87B6AEFC4B5E1F0252FFF470E4AF6957FE
*********************************************************
Mon, 08 Sep 2014 11:30:00 GMT ~ Nuvo Research® settles litigation with Mallinckrodt Pharmaceuticals
[CNW Group] - Nuvo Research® settles litigation with Mallinckrodt Pharmaceuticals
read full: http://finance.yahoo.com/news/nuvo-research-settles-litigation-mallinckrodt-113000152.html
*********************************************************
Thu, 04 Sep 2014 11:30:00 GMT ~ Nuvo Research® to Present at Rodman & Renshaw 16th Annual Global Investment Conference
[CNW Group] - Nuvo Research® to Present at Rodman & Renshaw 16th Annual Global Investment Conference
read full: http://finance.yahoo.com/news/nuvo-research-present-rodman-renshaw-113000954.html
*********************************************************
Fri, 01 Aug 2014 13:00:00 GMT ~ (T.NRI) (NRIFF): Nuvo Q2 Results In-Line, Looking Forward to WF10 Data Early 2015
read full: http://finance.yahoo.com/news/t-nri-nriff-nuvo-q2-130000440.html
*********************************************************
$NRIFF charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$NRIFF company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/NRIFF/company-info
Ticker: $NRIFF
OTC Market Place: OTC Pink Current
CIK code: 0001371679
Company name: Nuvo Research Inc.
Company website: http://www.nuvoresearch.com
Incorporated In: Canada
Business Description: Nuvo Research Inc. is a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10.
$NRIFF share structure
## source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$NRIFF extra dd links
Company name: Nuvo Research Inc.
Company website: http://www.nuvoresearch.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=NRIFF+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=NRIFF+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=NRIFF+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/NRIFF/news - http://finance.yahoo.com/q/h?s=NRIFF+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/NRIFF/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/NRIFF/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=NRIFF+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/NRIFF
DTCC (dtcc.com): http://search2.dtcc.com/?q=Nuvo+Research+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Nuvo+Research+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Nuvo+Research+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.nuvoresearch.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.nuvoresearch.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.nuvoresearch.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/NRIFF
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001371679&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/NRIFF/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/NRIFF/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=NRIFF&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=NRIFF
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/NRIFF/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=NRIFF+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=NRIFF+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=NRIFF
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=NRIFF
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=NRIFF+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/NRIFF/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=NRIFF+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/NRIFF.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=NRIFF
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/NRIFF/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/NRIFF
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/NRIFF
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/NRIFF:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=NRIFF
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=NRIFF
$NRIFF DD Notes ~ http://www.ddnotesmaker.com/NRIFF
follow_me
12 years ago
NRIFF received CRL from FDA regarding PENNSAID 2%.........
NUVO RESEARCH
ANNOUNCES
FDA RESPONSE TO PENNSAID
®
2% NDA
Mississauga, Ontario,
Canada
–
March 5,2013
–
Nuvo Research Inc. (Nuvo)(TSX:NRI)
announced today that its U.S. licensing partner, Mallinckrodt
,the Pharmaceuticals Business of Covidien
(NYSE:COV),has received a Complete Response Letter (CRL)from the U.S. Food and Drug Administration (FDA)following the review of
Mallinckrodt’s New Drug Application (NDA) for diclofenac sodium topical solution,2% w/w (PENNSAID 2%).
In the letter, the FDA requires that Mallinckrodt successfully complete a pharmacokinetic study comparing PENNSAID 2% to original PENNSAID 1.5%.
Similar pharmacokinetic studies submitted by Mallinckrodt with the NDA were not acceptable to the FDA because reserve samples were not retained at the clinical site. Pharma cokinetic studies are standard studies conducted during a drug development program to identify the total exposure or the amount of drug that reaches the blood stream after a patient receives both single and multiple doses of the product. Mallinckrodt has indicated to Nuvo
that it expects to complete the study and submit the results
to the FDA in the third calendar quarter of 2013, and that it
anticipates the FDA will provide a formal response to the filing
within 6 months thereafter. “While we are disappointed that
PENNSAID 2% will not be approved in this review cycle, we are
pleased that the FDA has outlined a clear pathway to approval that we believe can be completed in a relatively short time frame,
” said Dr. Bradley Galer, President of Nuvo’s Pain Group.“
Upon approval,PENNSAID 2% will be the first and only topical SAID in the US. featuring twice per day dosing and a
metered dose pump bottle.
PENNSAID 2% is a follow on product to original PENNSAID which is currently marketed in the U.S. by Mallinckrodt under license from Nuvo. PENNSAID 2% is a topical nonsteroidal anti-
inflammatory drug (NSAID) containing 2% diclofenac sodium compared to 1.5% for original PENNSAID. It is more
viscous than original PENNSAID, is supplied in a metered dose pump bottle and was studied in clinical trials using twice daily dosing compared to four times a day for original PENNSAID.
d.
follow_me
12 years ago
NUVO RESEARCH
ANNOUNCES
FDA RESPONSE TO PENNSAID
®
2% NDA
Mississauga, Ontario,
Canada
–
March 5,2013
–
Nuvo Research Inc. (Nuvo)(TSX:NRI)
announced today that its U.S. licensing partner, Mallinckrodt
,the Pharmaceuticals Business of Covidien
(NYSE:COV),has received a Complete Response Letter (CRL)from the U.S. Food and Drug Administration (FDA)following the review of
Mallinckrodt’s New Drug Application (NDA) for diclofenac sodium topical solution,2% w/w (PENNSAID 2%).
In the letter, the FDA requires that Mallinckrodt successfully complete a pharmacokinetic study comparing PENNSAID 2% to original PENNSAID 1.5%.
Similar pharmacokinetic studies submitted by Mallinckrodt with the NDA were not acceptable to the FDA because reserve samples were not retained at the clinical site. Pharma cokinetic studies are standard studies conducted during a drug development program to identify the total exposure or the amount of drug that reaches the blood stream after a patient receives both single and multiple doses of the product. Mallinckrodt has indicated to Nuvo
that it expects to complete the study and submit the results
to the FDA in the third calendar quarter of 2013, and that it
anticipates the FDA will provide a formal response to the filing
within 6 months thereafter. “While we are disappointed that
PENNSAID 2% will not be approved in this review cycle, we are
pleased that the FDA has outlined a clear pathway to approval that we believe can be completed in a relatively short time frame,
” said Dr. Bradley Galer, President of Nuvo’s Pain Group.“
Upon approval,PENNSAID 2% will be the first and only topical SAID in the US. featuring twice per day dosing and a
metered dose pump bottle.
PENNSAID 2% is a follow on product to original PENNSAID which is currently marketed in the U.S. by Mallinckrodt under license from Nuvo. PENNSAID 2% is a topical nonsteroidal anti-
inflammatory drug (NSAID) containing 2% diclofenac sodium compared to 1.5% for original PENNSAID. It is more
viscous than original PENNSAID, is supplied in a metered dose pump bottle and was studied in clinical trials using twice daily dosing compared to four times a day for original PENNSAID.
d.
Level up your trading with our powerful tools and real-time insights all in one place.
Renee
2 years ago
crookedneck
12 years ago
Hot Features
Premium
